|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Although nephropathies that are associated with variants in the apolipoprotein L1 gene (APOL1) often cause secondarily elevated blood pressure, they belong to the spectrum of focal segmental glomerulosclerosis and are not initiated by systemic hypertension.
|
26553514 |
2016 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Although APOL1-associated kidney disease is thought to account for a substantial proportion of ESKD in African Americans, not all the increased risk for ESKD is accounted for, and a complete cataloging of disparities in genetic causes of ESKD eludes our current understanding of genetic-associated kidney disease.
|
31606237 |
2019 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Although no biological evidence currently exists for the causality of APOL1 variants with kidney disease, our statistical reasoning provides a strong case for causality, and a region to target in future functional studies.
|
23438974 |
2013 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Although it was a small study cohort, our findings strongly suggest for the first time that two APOL1 risk alleles in young hypertensive African Americans with a family history of ESRD are strongly associated with kidney disease.
|
25530085 |
2015 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Among African Americans, the apolipoprotein L1 (<i>APOL1</i>) risk variants have been associated with various types of kidney disease and chronic kidney disease progression.
|
28572159 |
2017 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Among African-Americans, genome wide association revealed a strong correlation between the G1 and G2 alleles of APOL1 (apolipoproteinL1, also called trypanolytic factor) and kidney diseases including focal and segmental glomerulosclerosis, HIV-associated nephropathy and hypertensive nephrosclerosis.
|
23300552 |
2012 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
An evolving understanding of the pathogenesis of APOL1-mediated kidney damage may aid in personalized medicine approaches to APOL1 attributable kidney disease.
|
29406442 |
2018 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
An exception appears to be APOL1, which harbors common variants responsible for the high rate of FSGS and other nephropathies in people of recent African ancestry.
|
25168831 |
2014 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Approximately 12-13% of African Americans have two renal risk APOL1 variants but most do not develop kidney disease.
|
30507707 |
2019 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Because treatments for nondiabetic kidney disease may target this gene and its protein products, it remains critical to clarify the potential extrarenal effects of APOL1 kidney risk variants.
|
28143671 |
2017 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
By contrast, the significant survival advantage of AA dialysis patients was not observed in patients with ESRD attributed to other kidney disease (including polycystic kidney disease, interstitial nephritis, and pyelonephritis) and other GN, which are not associated with APOL1 variants.
|
30995638 |
2019 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Combined Effects of GSTM1 Null Allele and APOL1 Renal Risk Alleles in CKD Progression in the African American Study of Kidney Disease and Hypertension Trial.
|
26940095 |
2016 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Comparing the renal distribution of APOL1 in nondiabetic kidney disease to normal kidney suggests that a previously unrecognized arteriopathy may contribute to disease pathogenesis in patients of African ancestry.
|
21997392 |
2011 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Despite evidence of an association between variants at the apolipoprotein L1 gene (APOL1) locus and a spectrum of related kidney diseases, underlying biological mechanisms remain unknown.
|
26025194 |
2015 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Detection of APOL1 associations with kidney diseases and delineation of injury pathways brings hope for effective treatment for these kidney diseases.
|
30343724 |
2018 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Discovery of APOL1-associated nephropathy was a major success of the genetics revolution, demonstrating that secondary hypertension is typically present in nondiabetic African Americans with nephropathy.
|
22068337 |
2012 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Divers and colleagues report that among individuals with two APOL1 risk alleles, those with JC viruria are less likely to manifest kidney disease compared with those lacking JC viruria.
|
24280748 |
2013 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Existing data suggest that human immunodeficiency virus (HIV)-infected African Americans carrying 2 copies of the APOL1 risk alleles have greater risk of kidney disease than noncarriers.
|
25281610 |
2015 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Expanding the spectrum of APOL1-related renal disease: de novo collapsing glomerulopathy following kidney transplant.
|
30466562 |
2018 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
For example, the G1 and G2 variants of the APOL1 gene supporting control of Trypanosoma infection come with the trade-off that they promote the progression of kidney disease.
|
28481398 |
2017 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Further evidence supports risk modifiers in APOL1-associated nephropathy; some studies demonstrate that heterozygotes possess excess risk for ESKD or show earlier age at ESKD, relative to those with zero risk alleles.
|
28339911 |
2018 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Further studies are required to determine the effect of APOL1 risk variants on kidney diseases in other regions of sub-Saharan Africa.
|
25788523 |
2015 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Further studies to identify additional second hits are necessary to better understand the pathologic mechanisms of donor APOL1-associated kidney disease in the recipient.
|
30054024 |
2019 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, this model may facilitate the identification of APOL1-interacting molecules that could serve as new drug targets to treat <i>APOL1</i>-associated renal diseases.
|
27864430 |
2017 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene-gene interactions in APOL1-associated nephropathy.
|
24157943 |
2014 |